MYR's Series A Round

MYR raised a round of funding on April 03, 2012.

MYR is a German biotechnology company developing Myrcludex B, a drug for the treatment of chronic hepatitis B and delta virus infections. The drug inhibits the recently identified HBV receptor on the …

Articles about MYR's Series A Round: